FBIO (Fortress Biotech Inc.) stock: $2.51, $83.7M market cap, $196.6M cash, -$77.9M EV, $117.6M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
ZYCUBO
Approved · Active
Aliases copper histidinate, CUTX-101
Partnerships Sentynl Therapeutics: Rare Pediatric Disease PRV transferred to Cyprium per transaction; PRV sold for $205 million (closed March 30, 2026)
Indications- Menkes disease (pediatric patients) (Approved)
Status note FDA approved January 13, 2026 (Cyprium Therapeutics, a Fortress subsidiary); Rare Pediatric Disease PRV issued and monetized for $205M.
anselamimab
Phase 3 · Active Modality: monoclonal antibody
Aliases CAEL-101
Target amyloid light chain fibrils
Partnerships AstraZeneca (successor-in-interest to Alexion): strategic partnership; July 16, 2025 update — CARES primary endpoint not met (not statistically significant vs placebo); subgroup showed improvement in time to ACM/CVH; regulatory applications under review in Japan and by the EMA
Indications- AL amyloidosis, Mayo Stage IIIa and IIIb (Phase 3)
Status note Two ongoing global Phase 3 CARES studies (NCT04512235, NCT04504825). Phase 3 missed its primary endpoint (hierarchical combination of time to all-cause mortality and CV hospitalization frequency) per AstraZeneca, July 2025; program continues with applications under review in Japan and EMA.
dotinurad
Phase 2 · Active
Target URAT1
Partnerships Crystalys (via Fortress subsidiary Urica Therapeutics): closed $205M Series A (Oct 2025) to advance global Phase 3 gout studies
Indications- Gout (intolerant to xanthine oxidase inhibitors or failed uricase) (Phase 2)
Status note First patients dosed May 2026 in randomized, double-blind, placebo-controlled Phase 2 AMETHYST study (NCT07535034).
ATX-04
Preclinical · Active Modality: small molecule (selective beta-2-adrenergic agonist)
Aliases clenbuterol
Target beta-2 adrenergic receptor
Partnerships Duke University: exclusive worldwide license (Feb 2026); upfront + development/regulatory/commercial milestones; tiered low single-digit royalties
Indications- Pompe disease / lysosomal storage diseases (Preclinical)
Status note Avenue Therapeutics (Fortress partner company). Pre-technological-feasibility; license costs charged to R&D.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.